

- Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. *Cancer* 1989;63:364–367.
- Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from nongynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. *Cancer* 2000;88:358–363.
- Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2002;89:1545–1550.
- Sugarbaker PH. Peritonectomy procedures. *Ann Surg* 1995;221:29–42.
- Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. *J Surg Oncol* 2008;98:242–246.
- Sugarbaker PH, Graves T, DeBuijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. *Cancer Res* 1990;50:5790–5794.
- Sugarbaker PH. Management of peritoneal surface malignancy: the surgeon's role. *Langenbeck Arch Surg* 1999;384:576–587.
- Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2012;99:699–705.
- Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. *Eur J Surg Oncol* 2006;32:948–953.
- Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. *Int J Cancer* 2011;128:2717–2725.
- Dawson LE, Russell AH, Tong D, et al. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. *J Surg Oncol* 1983;22:95–99.
- Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. *Dis Colon Rectum* 1991;34:723–727.
- Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. *Cancer Metastasis Rev* 2003;22:465–472.
- Weiss L. Metastatic inefficiency: causes and consequences. *Cancer Res* 1986;3:1–24.
- Gilly FN, Cotte E, Brigand C, et al. Quantitative prognostic indices in peritoneal carcinomatosis. *Eur J Surg Oncol* 2006;32:597–601.
- Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. *Int Semin Surg Oncol* 2005;2:3.
- Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” *Am J Surg Pathol* 1995;19:1390–1408.
- Sugarbaker PH. Epithelial appendiceal neoplasms. *Cancer J* 2009;15:225–235.
- Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J Clin Oncol* 2009;27:6237–6242.
- Cerruto CA, Brun EA, Chang D, et al. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. *Arch Pathol Lab Med* 2006;130:1654–1661.
- Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. *J Exp Clin Cancer Res* 1996;15:49–58.
- Jacquet P, Jelinek JS, Chang D, et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. *J Am Coll Surg* 1995;181:530–538.
- Yan TD, Haveric N, Carmignani CP, et al. Computed tomographic characterization of malignant peritoneal mesothelioma. *Tumori* 2005;91:394–400.
- Jacquet P, Jelinek JS, Steves MA, et al. Evaluation of computer tomography in patients with peritoneal carcinomatosis. *Cancer* 1993;72:1631–1636.
- Pestieu SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. *Dis Colon Rectum* 2000;43:1341–1346, discussion 1347–1348.
- Sammartino P, Sibio S, Biacchi D, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: Preliminary results of surgery plus prophylactic HIPEC. *Gastroenterol Res Pract* 2012;2012:141585.
- Braam HJ, Boerma D, Wiersema MJ, et al. Hyperthermic perioperative chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. *Eur J Surg Oncol* 2013;39:988–993.
- Elias D, Goere D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. *Ann Surg* 2008;247:445–450.
- Sugarbaker PH. Comprehensive management of disseminated colorectal cancer. *Ann Surg Oncol* 2008;15:3327–3330.
- Delhorme JB, Triki E, Zeca I, et al. Mandatory second-look surgery after surgical treatment of peritoneal carcinomatosis of colonic origin. (personal communication)
- Honore C, Goere D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. *Ann Surg Oncol* 2013;20:183–192.
- Tsujimoto H, Hiraki S, Sakamoto N, et al. Outcome after emergency surgery in patients with a free perforation caused by gastric cancer. *Exp Ther Med* 2010;1:199–203.
- Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. *Eur J Surg Oncol* 2008;34:196–201.
- Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. *Ann Surg* 1994;219:109–111.
- Ronnett BM, Shmookler BM, Sugarbaker PH, et al. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. *Anat Pathol* 1997;2:197–226.
- Bruin S, Verwaal VJ, Vincent A, et al. A clinicopathologic analysis of peritoneal metastases from colorectal and appendiceal origin. *Ann Surg Oncol* 2010;17:2330–2340.
- Smeenk RM, Verwaal VJ, Antonini N, et al. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. *Ann Surg Oncol* 2007;14:493–499.
- Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. *Ann Surg Oncol* 2007;14:2289–2299.
- Kusamura S, Baratti D, Virzi S, et al. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. *J Surg Oncol* 2013;107:312–319.
- Verwaal VJ, van Tinteren H, Ruth SV, et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. *J Surg Oncol* 2004;85:61–67.
- Moran BJ. Establishment of a peritoneal malignancy treatment centre in the United Kingdom. *Eur J Surg Oncol* 2006;32:614–618.
- Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. *Br J Surg* 2007;94:1408–1414.
- Rosen SA, Buell JF, Yohida A, et al. Initial presentation with stage IV colorectal cancer. *Arch Surg* 2000;135:530–534.
- Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. *Int Radiat Oncol Biol Phys* 1983;9:361–365.
- Elias D, Benizri E, Pocard M, et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. *Eur J Surg Oncol* 2006;32:632–636.
- da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. *J Am Coll Surg* 2006;203:878–886.
- Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 2010;28:63–68.
- Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: Nationwide long-term outcome following the Dutch Protocol. *Ann Surg Oncol* 2013;20:4224–4230.
- Koga S, Hamazoe R, Maeta M, et al. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. *Cancer Res* 1984;44:1840–1842.
- Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. *J Clin Oncol* 2009;27:681–685.
- Verwaal VC, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis from colorectal cancer. *J Clin Oncol* 2003;21:3737–3743.
- Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol* 2005;12:65–71.
- Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin. *Gastroenterol Clin Biol* 2006;30:1200–1204.
- Elias D. Peritoneal carcinomatosis or liver metastases from colorectal cancer: similar standards for a curative surgery? *Ann Surg Oncol* 2004;11:122–123.
- Sugarbaker PH. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. *Int J Surg Oncol* 2011;2011:915078.
- Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. *Br J Surg* 2004;91:739–746.
- de Pangher Manzini V, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. *Ann Oncol* 2010;21:348–353.
- Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. *Surg Oncol Clin North Am* 2003;12:605–621, xi.
- Carteni G, Manegold C, Martin Garcia G, et al. Malignant peritoneal mesothelioma. Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. *Lung Cancer* 2009;64:211–218.

60. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. *Eur J Surg Oncol* 2006;32:676–681.
61. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. *J Clin Oncol* 2003;21:4560–4567.
62. Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. *Eur J Surg Oncol* 2006;32:686–691.
63. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. *Ann Surg Oncol* 2006;13:229–237.
64. Deraco M, Baratti D, Zaffaroni N, et al. Advances in clinical research and management of diffuse peritoneal mesothelioma. *Recent Results Cancer Res* 2007;169:137–155.
65. Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. *J Surg Oncol* 2008;98:268–272.
66. Hioki M, Gotohda N, Konishi M, et al. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. *World J Surg* 2010;34:555–562.
67. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. *Lancet Oncol* 2004;5:219–228.
68. Boku N. Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group. Chemotherapy for metastatic disease: review from JCOG trials. *Int J Clin Oncol* 2008;13:196–200.
69. Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. *Br J Surg* 2005;92:370–375.
70. Glehen O, Cotte E, Sayag-Beaujard AC, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. *Arch Surg* 2004;139:20–26.
71. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. *Cancer* 1997;79:884–891.
72. Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. *Ann Surg Oncol* 2010;17:2370–2377.
73. Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. *Surgery* 1996;119:437–444.
74. Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. *J Gastrointest Surg* 2004;8:454–463.
75. Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy. *Cancer J* 2009;15:196–199.
76. Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. *Ann Surg Oncol* 2007;14:2270–2280.
77. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. *Ann Surg Oncol* 2011;18:1575–1581.
78. Prospektive multizentrische Phase III-Studie zur zytoreduktiven Chirurgie mit hyperthermer intraperitonealer Chemoperfusion nach präoperativer Chemotherapie beim Magenkarzinom inkl. AEG mit primärer peritonealer Metastasierung (Gastripec I). EudraCT-Number: 2006-006088-22 Phase III-Trial.
79. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. *Hepatogastroenterology* 2001;48:1776–1782.
80. Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. *Cancer* 1999;85:529–534.
81. Kim JY, Bae HS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermic chemo-perfusion (IHCP). *Gastric Cancer* 2001;4:27–33.
82. Zhu ZG, Tang R, Yan M, et al. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study. *Dig Surg* 2006;23:93–102.
83. Scaringi S, Kiammanesh R, Sabate JM, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal-chemotherapy: a single Western center experience. *Eur J Surg Oncol* 2008;34:1246–1252.
84. De Roover A, Detroz B, Detry O, et al. Adjuvant hyperthermic intraperitoneal preoperative chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma. An initial experience. *Acta Chir Belg* 2006;106:297–301.
85. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. *Ann Surg Oncol* 2007;14:2702–2713.
86. Xu DZ, Zhan YQ, Sun XW, et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. *World J Gastroenterol* 2004;10:2727–2730.
87. D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma (GASTRICHIP). ClinicalTrials.gov Identifier: NCT01882933 (<http://clinicaltrials.gov/show/NCT01882933>).
88. Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. *Int J Gynecol Cancer* 2010;20:61–69.
89. Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. *Ann Surg Oncol* 2012;19:2352–2359.
90. Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: A multicenter, prospective study of 246 patients. *Ann Surg Oncol* 2012;19:4052–4058.
91. Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. *Eur J Surg Oncol* 2013;39:1435–1443.
92. Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. *Gynecol Oncol* 2012;127:502–505.
93. Deraco M, Kusamura S, Virzi S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. *Gynecol Oncol* 2011;122:215–220.
94. Karakousis CP, Kontzoglou K, Driscoll DL. Intraperitoneal chemotherapy in disseminated abdominal sarcoma. *Ann Surg Oncol* 1997;4:496–498.
95. Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. *Cancer* 2002;94:2441–2446.
96. Berthet B, Sugarbaker TA, Chang D, et al. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. *Eur J Cancer* 1999;35:413–419.
97. Eilber FC, Rosen G, Forscher C, et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. *Ann Surg Oncol* 1999;6:645–650.
98. Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. *Cancer* 2004;100:1943–1950.
99. Bonvalot S, Cavalcanti A, Le Pechoux C, et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. *Eur J Surg Oncol* 2005;31:917–923.
100. Baratti D, Pennacchioli E, Kusamura S, et al. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010;17:3220–3228.
101. Rossi CR, Casali P, Kusamura S, et al. The consensus statement on the locoregional treatment of abdominal sarcomatosis. *J Surg Oncol* 2008;98:291–294.